Evidence map›Paper›PMID 37452874›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Can physiologic colonic [

Christos Sachpekidis, Christoph K Stein-Thoeringer, Annette Kopp-Schneider, Vivienn Weru, Antonia Dimitrakopoulou-Strauss, Jessica C Hassel

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. The Prognostic Value of Biomarkers Identified by [Diagnostics (Basel, Switzerland) · 2025
    Article
  4. Multi-Organ metabolic profiling with [European journal of nuclear medicine and molecular imaging · 2025
    Article
  5. Article
  6. Article
  7. The Combined Prognostic Value ofCancer medicine · 2025
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Christos SachpekidisClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. christos_saxpe@yahoo.gr.ORCID 0000-0001-8739-8741
Christoph K Stein-ThoeringerLaboratory of Translational, Microbiome Science, Internal Medicine I, University Clinic Tuebingen, Tuebingen, Germany.
Annette Kopp-SchneiderDepartment of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Vivienn WeruDepartment of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Antonia Dimitrakopoulou-Strauss *Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.
Jessica C Hassel *Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Research Center · DEHeidelberg University · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and prognosticator in oncological patients under immunotherapy. Aim of the present study is to investigate if physiologic colonic [ METHODOLOGY: One hundred nineteen stage IV melanoma patients scheduled for immunotherapy with ipilimumab, applied either as monotherapy or in combination with nivolumab, underwent baseline [

resultsMedian follow-up [95%CI] from the beginning of immunotherapy was 64.6 months [61.0-68.6 months]. Best response to treatment was progressive disease (PD) for 60 patients, stable disease (SD) for 37 patients, partial response (PR) for 18 patients, and complete response (CR) for 4 patients. Kaplan-Meier curves demonstrated a trend for longer PFS and OS in patients with lower colonic SUV and CLR values; however, no statistical significance for these parameters as prognostic factors was demonstrated. On the other hand, patients showing disease control as best response to treatment (SD, PR, CR) had significantly lower colonic MTV and TLG than those showing PD. With regard to lymphoid cell-rich organs, significantly lower baseline SLR

conclusionsPhysiologic colonic [

Indexed as

ColonFluorodeoxyglucose F18ImmunotherapyMelanomaPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overBiological TransportFemaleHumansMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeFluorodeoxyglucose F18[18F]FDG colonic uptakeGut microbiomeImmunotherapyLipopolysaccharide (LPS)Metastatic melanomaMTVPET/CTSUVTLG

Identifiers

PMID37452874
PMCPMC10547632
OpenAlexW4384407303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.